pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Lucentis
drug
save

ranibizumab

Marketedupdated 3mo ago
by Genentech Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval18 co-mentions · 9 sources
  • drugBYOOVIZ16 co-mentions · 8 sources
  • drugranibizumab SR14 co-mentions · 14 sources
  • drugranibizumab biosimilar13 co-mentions · 13 sources
  • companySamsung Bioepis Co Ltd8 co-mentions · 8 sources
  • companyXbrane Biopharma AB5 co-mentions · 5 sources
  • tagOphthalmology5 co-mentions · 5 sources
  • tagBiosimilar5 co-mentions · 5 sources

indications

investigational
Diabetic Macular Edema

all catalysts(0)

nothing on the calendar yet

Trials studying ranibizumab

  • phase2Study of Zifibancimig in Participants With Neovascular Age-related Macular Degenerationactive not recruitingn=177
  • phase2Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDenrolling by invitationn=116
  • phase3A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMDrecruitingn=250
  • phase3A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)completedn=400
  • phase3A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopiacompletedn=280
  • phase3Extension Study for the Port Delivery System With Ranibizumab (Portal)recruitingn=1,000
  • phase3Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)recruitingn=561
  • phase2A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edemacompletedn=394
more trials →

News(2)

  • EyePoint plummets on pivotal data for main drug
    Though its drug missed the main goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be harder to win over, however.
    biopharma_dive · 15h ago
  • Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
    This webinar provides an assessment of recent job market activity across biopharma and explores how companies approaching commercial readiness or building out sales and marketing teams can navigate…
    biospace · 26d ago
brand
Lucentis
generic
ranibizumab
indication
Choroidal Neovascularization
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 6m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?